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RESUMO
Introdução: Os objetivos foram a determinação da prevalência de défice de ferro e de eventuais diferenças entre os doentes obesos 
com e sem síndrome metabólica. 
Material e Métodos: Análise dos doentes observados na consulta multidisciplinar de obesidade na nossa instituição entre 2013 e 2015 
(n = 260). Défice de ferro: ferritina < 15 ng/mL. Critérios de exclusão: cirurgia bariátrica prévia, ausência de doseamentos de ferritina 
e de hemoglobina. 
Resultados: Avaliaram-se 215 doentes (84,2% mulheres) com uma idade média de 42,0 ± 10,3 anos. O índice de massa corporal 
mediano foi 42,5 (40,0 - 46,8) kg/m2 e 52,1% apresentavam síndrome metabólica. O défice de ferro estava presente em 7,0% sem 
diferenças entre os géneros e entre os doentes com e sem síndrome metabólica. A hipertensão associou-se a menor prevalência de 
défice de ferro. Doentes com diabetes tipo 2 e hipertensão apresentaram valores mais elevados de ferritina. Na análise multivariada, 
a síndrome metabólica e o índice de massa corporal constituíram fatores preditivos de défice de ferro, enquanto a hipertensão se 
associou a um menor risco. 
Discussão: A prevalência de défice de ferro foi similar a estudos previamente publicados. O défice de ferro pode ser subdiagnosticado 
se baseado apenas nas concentrações de ferritina. No nosso estudo, a diabetes e a hipertensão parecem contribuir para os níveis 
elevados de ferritina descritos na obesidade. 
Conclusão: A ferritina poderá não ser um índice fiável para avaliação de reservas de ferro na obesidade, particularmente quando 
associada a diabetes tipo 2 e hipertensão. São necessários mais estudos de forma a orientar o diagnóstico e a suplementação com 
ferro nestes doentes. 
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ABSTRACT
Introduction: We aim to define the iron deficiency prevalence and eventual differences between obese patients with and without 
metabolic syndrome.
Material and Methods: Analysis of patients evaluated at multidisciplinary consultation of obesity in our institution between 2013 
and 2015 (n = 260). Iron deficiency: ferritin levels < 15 ng/mL. Exclusion criteria: prior bariatric surgery; lack of ferritin or hemoglobin 
determinations. 
Results: We analyzed data from 215 patients (84.2% female) with a mean age of 42.0 ± 10.3 years. The median body mass index 
was 42.5 (40.0 - 46.8) kg/m2 and 52.1% had metabolic syndrome. Iron deficiency was present in 7.0%, with no differences between 
genders or between patients with or without metabolic syndrome. Hypertension was associated with lower prevalence of iron deficiency. 
Type 2 diabetes and hypertension patients had higher levels of ferritin. The multivariate analysis showed that metabolic syndrome and 
increasing body mass index were predictive of higher risk of iron deficiency while hypertension predicted lower odds of iron deficiency.
Discussion: The prevalence of iron deficiency was similar in other published studies. Iron deficiency may be underdiagnosed if based 
only on ferritin concentrations. In our study, diabetes and hypertension appear to contribute to the increase in ferritin levels described 
in obesity.
Conclusion: Ferritin may not be a reliable index for evaluating iron stores in obese patients, particularly when associated with 
comorbidities such as type 2 diabetes and hypertension. Further studies are needed to guide the diagnosis and iron supplementation 
in these patients.
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INTRODUCTION
 Obesity and iron deficiency (ID) are diseases with 
epidemic proportions and share a strong link.1,2 ID with or 
without anemia is amongst the most commonly reported 
nutritional deficiencies in patients undergoing bariatric 
surgery (BS).3 ID may worsen the burden of obesity and 
complicate weight management. Fatigue, depression and 
reduced exercise capacity associated with ID may reduce 
the efficacy of behavioral weight management treatments.4–6
 The etiology of ID in patients with obesity appears 
to be multifactorial. Although different explanations for 
ID have been described among obese individuals, the 
current explanation is the accompanying chronic low-
level inflammatory state as it reduces iron absorption and 
increases reticuloendothelial iron sequestration. Support 
for an inflammatory cause for the ID of obesity results from 
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are usually suppressed when body iron stores are low, tend 
to be high and inversely related to transferrin saturation 
in obesity.4,7–9 Ferritin, as an acute-phase reactant, is 
increased in conditions associated with inflammation and 
previous studies have documented normal or elevated 
levels of ferritin even in the presence of true iron deficiency.1
 In contrast, there is increasing evidence supporting 
the association between elevated iron stores and adverse 
health outcomes. Elevated ferritin levels have been 
independently associated and are a predictive factor for 
metabolic syndrome (MetS), type 2 diabetes (T2DM) and 
obesity.10–13 
 The iron homeostasis in obesity may be a two-faced 
clinical condition. On one hand, obesity may promote iron 
deficiency and on the other hand the presence of a condition 
termed “dysmetabolic iron overload syndrome” (DIOS) has 
become the most frequent differential diagnosis for elevated 
ferritin concentrations in patients with metabolic syndrome 
(MetS) or nonalcoholic fatty liver disease (NAFLD). DIOS 
is characterized by increased serum ferritin concentrations 
with normal or mildly elevated transferrin saturation and 
true iron overload is rarely found in those patients.5
 As the iron metabolism remains unclear in these 
populations, the purposes of this study were to determine 
the prevalence of ID and evaluate the presence of eventual 
differences between obese patients with and without 
metabolic syndrome (MS).
MATERIAL AND METHODS
Patients and data collection
 We selected participants in this cross-sectional study 
among the candidates evaluated at the multidisciplinary 
obesity clinic at our institution between 2013 and 2015. The 
multidisciplinary consultation includes endocrinologists, 
nutritionists, and general surgeons. Patients with BS criteria 
[body mass index (BMI) > 40 kg/m2 or BMI > 35 kg/m2 with 
comorbidities] are evaluated preoperatively and followed-
up after BS.
 Exclusion criteria included history of prior BS (n = 33) 
and lack of ferritin and hemoglobin (Hb) determinations 
obtained at the same time during pre-surgical evaluation (n 
= 21). 
 The local ethics committee approved this study.
 Clinical, anthropometric, biochemical, and hematological 
pre-surgical parameters were analyzed. Weight and height 
were measured in the first visit. Diagnosis of type 2 diabetes 
(T2DM), hypertension, dyslipidemia, and metabolic 
syndrome (MetS) were based on medical history and 
laboratory data.
Laboratory measurements
 All laboratory measurements were performed on 
fasting blood samples. The biochemical parameters 
analyzed included measurement of fasting serum glucose, 
glycosylated hemoglobin (HbA1c), insulin, total cholesterol 
(TC), high-density lipoprotein cholesterol (HDL-c), low-
density lipoprotein cholesterol (LDL-c), triglycerides (TG), 
hemoglobin, hematocrit, mean corpuscular hemoglobin 
concentration (MCHC), mean corpuscular volume (MCV), 
ferritin, transferrin and serum iron. These parameters were 
measured by standard laboratory techniques used in clinical 
chemistry laboratories. 
Definitions
 According to the WHO definition, ferritin levels under 
15 ng/mL were considered as absolute iron deficiency (ID) 
and values of hemoglobin (Hb) under 13 g/dL and 12 g/
dL in men and in women, respectively, were considered 
diagnostic of anemia.14,15 
 The definition of MetS by the updated National 
Cholesterol Education Program (NCEP) Adult Treatment 
Panel (ATP) III was used. Therefore, MetS was considered 
as the presence of any three of the following five traits: (a) 
abdominal obesity, defined as a waist circumference ≥ 102 
cm in men and ≥ 88 cm in women; (b) serum TG ≥ 150 mg/
dL or drug treatment for elevated TG; (c) serum HDL-c < 40 
mg/dL in men and < 50 mg/dL in women or drug treatment 
for low HDL-c; (d) blood pressure ≥ 130/85 mmHg or drug 
treatment for elevated blood pressure; (e) fasting plasma 
glucose ≥ 100 mg/dL or drug treatment for elevated blood 
glucose.16
Statistical analysis
 Normal distribution of the variables was evaluated 
using the Kolmogorov–Smirnov test. Comparisons between 
groups were performed using t test (normal distribution) and 
Mann-Whitney test (non-normal distribution) for continuous 
variables and the χ2 test for categorical variables. The 
relationships between the continuous variables were 
examined by the Spearman’s linear correlation test. 
 To assess the variables independently related to ID 
in all the individuals included in the study, multiple binary 
regression analyses were performed. ID was considered as 
the dependent variable and the independent variables were 
age, sex (male/female), BMI, HbA1c, hypertension (yes/no) 
and T2DM (yes/no).
 Statistical significance was accepted at the level of 
p < 0.05. Statistical analyses were performed with the 
program IBM SSPS version 20.
RESULTS
 This study included 215 patients, 84.2% (n = 181) 
females and a mean age of 42.0 ± 10.3 years. The median 
BMI was 42.5 (IQR 40.0-46.8) kg/m2 and MetS was present 
in 52.1% (n = 112) of patients. Table 1 describes the detailed 
patient’s characteristics. 
 Absolute iron deficiency was present in 7.0% (n = 
15) There were no differences between genders (0.0% 
vs 8.3%; p = 0.14). As showed in Table 2, we found no 
differences between patients with or without MetS (8.0% vs 
5.8%; p = 0.52). Also, there were no differences between 
iron metabolism indices and hematological parameters in 
patients with or without MetS. 
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element of MetS. We found that patients with T2DM (25.1%; 
n = 54) had higher levels of ferritin (117.5 vs 63.0; p = 0.009) 
although no differences in the prevalence of ID were shown 
(3.7% vs 8.1%; p = 0.37). 
 Hypertensive patients (45.6%; n = 98) had higher levels 
of ferritin (83.0 vs 58.0; p = 0.029) and lower prevalence of 
ID (3.1% vs 10.3%; p = 0.04). 
 Between patients with (n = 73) and without dyslipidemia 
(n = 142), there were no differences in ferritin levels (79.0 
vs 64.5; p = 0.62) or in the prevalence of ID (7.7% vs 5.2%; 
p = 0.76). 
 Positive correlations between ferritin and serum iron (r = 
0.38; p < 0.001), glycaemia (r = 0.26; p < 0.001) and insulin 
(r = 0.19; p = 0.005) were verified. There were no significant 
correlations between ferritin and BMI (r = -0.31; p = 0.651) 
or weight (r = 1.18; p = 0.083). 
 We performed a logistic regression (Table 3) to establish 
the effects of age, gender, BMI and the presence of MetS, 
hypertension, dyslipidemia and T2DM on the probability 
of having ID. The presence of MetS predicts a higher risk 
of ID while the presence of hypertension was associated 
with a lower risk of ID. Increasing BMI was independently 
associated with ID, and for every unit increase in BMI the 
odds of ID increases 0.09.
DISCUSSION
 In our study, ID was present in 7.0% of patients.  This 
percentage may be underestimated due to the higher values 
of ferritin reported in patients with chronic inflammation. In 
our study, diabetes and hypertension appear to contribute 
Table 1 - Characteristics of study population (n = 215)
Variables Results Variables Results 
  Sex, (%) (M/F)   M: 15.8  F: 84.2   Fasting glucose (mg/dL), median (IQR)   94.0 (88.0 - 107.0)
  Age (years), mean ± SD   42.0 ± 10.3   HbA1c (%), median (IQR)   5.6 (5.3 - 6.0)
  BMI (kg/m2), median (IQR)   42.5 (40.0 - 46.8)   Insulin (mg/dL), median (IQR)  14.7 (10.1 - 24.3)
  Weight (kg), median (IQR)   112.0 (100 - 126.0)   Total cholesterol (mg/dL), median (IQR)  183.0 (165.0 - 215.0)
  MetS, % (n)   52.1 (112)   HDL-c (mg/dL), median (IQR)   47.0 (39.0 - 54.0)
  Dyslipidemia, % (n)   73.0 (157)   LDL-c (mg/dL), median (IQR)   112.0 (97.0 - 139.0)
 Hypertension, % (n)  45.6 (98)   Triglycerides (mg/dL), median (IQR)  118.0 (92.0 - 169.0)
  T2DM, % (n)  25.1 (54)   C-reactive protein (mg/L), median (IQR)   8.02 (4.0 - 13.6)
M: male; F: female; SD: standard deviation; BMI: body mass index; IQR: interquartile range; MetS: metabolic syndrome; T2DM: type 2 diabetes mellitus; HbA1c: glycated hemoglobin; 
HDL-C: high density lipoprotein cholesterol; LDL-c: low density lipoprotein cholesterol
Table 2 - Hematological parameters according to the presence of Metabolic Syndrome (MetS)
Variables MetS (n = 112) No MetS (n = 103) All (n = 215) p value
  Hemoglobin (g/dL), median (IQR)   13.6 (13.1 - 14.6)   13.9 (13.2 - 14.5)   13.7 (13.1 - 14.5)   0.514†
  Hematocrit (%), median (IQR)   40.4 (39.0 - 42.5)   40.9 (38.8 - 42.7)   40.6 (38.9 - 42.6)   0.878†
  MCHC (g/dL), median (IQR)   33.9 (33.2 - 34.6)   34.0 (33.3 - 34.6)   33.9 (33.3 - 34.6)   0.461†
  MCV (fl), median (IQR)   86.1 (83.2 - 88.9)   85.4 (82.6 - 87.7)   85.5 (83.0 - 88.3)   0.09†
  C-reactive protein (mg/L) median (IQR)   7.74 (3.9 - 11.6)   9.19 (4.5 - 14.4)   8.02 (4.0 - 13.6)   0.16†
  Ferritin (ng/dL) , median (IQR)   83.0 (36.3  -185.5)   64.0 (35.0 - 123.0)   73.0 (36.0 - 155.0)   0.16†
  Transferrin (mg/dL), median (IQR)   281.0 (248.8 - 316.5)   281.0 (263.0 - 315.0)   281.0 (258.0 - 315.5)   0.253†
  Iron (ug/dL), median (IQR)   75.0 (55.3 - 91.0)   73.0 (56.0 - 100.0)   74.0 (56.0 - 94.0)   0.825†
  Iron deficiency, % (n)   8.0 (9)   5.8 (6)   7.0 (15)   0.52**
  Anemia, % (n)   7.1 (8)   4.9 (5)   6.0 (13)   0.48**
IQR: interquartile range; MCHC: mean corpuscular hemoglobin concentration; MCV: mean corpuscular volume; † Mann-Whitney U test; ** Fisher’s exact test
Table 3 - Analysis of predictors of iron deficiency (Logistic regression model)
  Variables Regression coefficient OR p value 95% C.I. for OR
    Age   0.038   1.039   0.274   0.97 - 1.113
    Gender (female)   18.271   86072754.4   0.998   -
    BMI (kg/m2)   0.094   1.099   0.035   1.007 - 1.199
    Metabolic syndrome   1.632   5.113   0.030   1.17 - 22.357
    Hypertension  -2.394   0.091   0.008   0.016 - 0.533
    T2DM  -1.357   0.257   0.137   0.043 - 1.542
    Dyslipidemia  -0.140   0.870   0.863   0.179 - 4.234
BMI: body mass index T2DM: type 2 diabetes mellitus
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to the increase in ferritin levels described in obesity. It is 
important to understand that hyperferritinaemia does not 
necessarily mean the presence of true iron overload. 
 A comparable prevalence (8.7%) of iron deficiency were 
reported in the studies of Careaga et al and Sánchez et 
al3,17 Other studies have reported varying ID prevalence’s in 
patients prior BS and those differences can be explained, in 
part, by the different criteria applied to define ID.18,19
 According to our logistic regression model, a higher 
BMI was independently associated with a higher risk of ID. 
This finding is in agreement with a recent meta-analysis 
that showed that obesity was associated with ID, although 
studies with a ferritin-based diagnosis of ID more frequently 
conclude that obesity is not associated with ID.1 The etiology 
of obesity associated ID remains unclear and several 
mechanisms have been proposed as consumption of a 
poorly balanced diet, increased iron requirements due to 
larger blood volume and size and, more recently, hepcidin-
mediated iron sequestration.1,7 We could not demonstrate 
a correlation between BMI and ferritin levels, suggesting 
minimal chronic inflammation in our obese patients or 
minimal influence of chronic inflammation in ferritin levels. 
Considering C-reactive protein has low specificity and we 
lack levels of ultrasensitive C-reactive protein, we cannot 
infer about inflammation status.
 Our study demonstrated that MetS is associated with a 
higher odds of ID, which is in contrast with the studies that 
reported higher ferritin levels in patients with MetS probably 
due to low chronic inflammation.20–22 In fact, although without 
statistical differences due to sample size and overall lower 
prevalence of ID, patients with MetS criteria in our study 
had higher median levels of ferritin and more patients had 
ID. This could reflect the complexity of iron metabolism in 
low chronic inflammation status and that ferritin levels may 
not be a reliable index to diagnose ID in those patients.  
 Patients with T2DM had higher levels of ferritin and we 
found a positive correlation between ferritin and glucose 
and insulin. This is in agreement with published literature as 
several studies also have reported higher levels of ferritin 
in patients with DM2. Moreover, prospective studies have 
shown that ferritin concentrations independently predict 
the development of T2DM.23–25 However, T2DM was not 
independently associated with the risk of ID in our logistic 
regression model.
 Also in agreement with other studies, our patients with 
hypertension had higher ferritin levels and consequently, 
lower prevalence of ID. We demonstrated that hypertension 
was independently associated with a lower risk of ID, 
which is in agreement with the higher levels reported in 
hypertensive patients. An independent association between 
higher ferritin levels and the risk of hypertension have also 
been reported.26,27
Limitations
 This study reflects a small sample of patients evaluated 
retrospectively and without a control group. In the future, 
prospective randomized control trials could help to establish 
a cause-effect relation.
 The absence of determinations of ultrasensitive 
C-reactive protein and other iron metabolism indices, 
as hepcidin and soluble transferrin receptor, limits our 
interpretation of the results and evaluation of the deficit or 
iron overload.
CONCLUSION
 The iron metabolism in these patients is heterogeneous, 
complex, and still not fully understood. 
 According to our results, ferritin may not be a reliable 
index for evaluating iron stores in obese patients, particularly 
when associated with comorbidities such as T2DM and 
hypertension. ID may be underdiagnosed if based only on 
ferritin concentrations.  
 Evaluation and replenishment of ID in patients with 
obesity are important prior to BS to minimize the deterioration 
after surgery. However, it has been advocated that iron 
excess increased the risk of important comorbidities. Also, 
several studies have showed that the mechanisms for iron 
absorption are disrupted in obesity. As both iron deficiency 
and overload may have detrimental effects further studies 
are needed to guide the diagnosis of ID and the eventual 
need of iron replenishment. ID diagnosis should be based 
on other indices not affected by the acute-phase response 
in order to differentiate true deficits from secondary changes 
to states of chronic inflammation. 
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